BCIQ Profiles

Company Profile ReportTarget Profile Report
0902 QTs
BioCentury & Getty Images

Product Development

Sept. 2 Quick Takes: Forte drops lone clinical asset

Disc’s crossover round brings in $90M, plus Takeda, BeiGene, Innovent and more

Sep 3, 2021 | 2:27 AM GMT

Forte Biosciences Inc. (NASDAQ:FBRX) is discontinuing FB-401, its lone disclosed program, after the atopic dermatitis therapy missed the primary endpoint of EASI-50 in Phase II testing. Forte, which had

Read the full 596 word article

How to gain access

Continue reading with a
two-week free trial.